Stay updated on Pembrolizumab in Lymphoma Subtypes Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Subtypes Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPage updated to Revision: v3.4.2. The previous funding-status notice (v3.4.1) and related operating-status messaging have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary display added; QC-related field labels and FEAR Act labeling adjusted; page revision tag updated to v3.4.0.SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated to v3.3.4 (replacing v3.3.3); this appears to be a minor site update with no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded the Maryland location under Locations and updated the page revision to v3.3.3. Removed the Maryland Locations footer item and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision: v3.3.2 was added and v3.3.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Lymphoma Subtypes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.